STEEPLE研究PPT课件.pptVIP

Safety and Efficacy of Intravenous Enoxaparin in Elective Percutaneous Coronary Intervention: an International Randomized Evaluation (STEEPLE) STEEPLE Trial: Primary Endpoint at 48 hours STEEPLE Trial: Primary Endpoint at 48 hours STEEPLE Trial Summary Among patients undergoing non-emergent PCI, treatment with reduced dose enoxaparin was associated with lower rates of major or minor bleeding by 48 hours post-PCI compared with treatment with ACT-driven UFH. Patient enrollment in the enoxaparin 0.5 mg/kg treatment group was discontinued by the data safety monitoring committee near the end of the